Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2025 · 10-K
Revenue$205.45M$205.45M+12.9% vs Q4 2024 Net Income$16.96M$16.96M+35.3% vs Q4 2024 EPS Diluted$0.46$0.46+27.8% vs Q4 2024 Gross Profit$128,378,000+30.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$123,048,000+45.4% Free Cash Flowderived$122,359,000+45.5% Margins · derivedGross margin62.5%+8.5 pt vs Q4 2024
Operating margin29.6%+8.6 pt vs Q4 2024
Net margin8.3%+1.4 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end